{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T13:47:41Z","timestamp":1773150461857,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"published-print":{"date-parts":[[2012,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Use of atypical antipsychotics (AA) in combination with an antidepressant is recommended as an augmentation strategy for patients with depression. However, there is a paucity of data comparing aripiprazole and other AAs in terms of patient reported outcomes. Therefore, the objective of this study was to examine the levels of HRQoL and health utility scores in patients with depression using aripiprazole compared with patients using olanzapine, quetiapine, risperidone and ziprasidone.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Data were obtained from the 2009, 2010, and 2011 National Health and Wellness Survey (NHWS), a cross-sectional, internet-based survey that is representative of the adult US population. Only those patients who reported being diagnosed with depression and taking an antidepressant and an atypical antipsychotic for depression were included. Patients taking an atypical antipsychotic for less than 2\u2009months or who reported being diagnosed with bipolar disorder or schizophrenia were excluded. Patients taking aripiprazole were compared with patients taking other atypical antipsychotics. Health-related quality of life (HRQoL) and health utilities were assessed using the Short Form 12-item (SF-12) health survey. Differences between groups were analyzed using General Linear Models (GLM) controlling for demographic and health characteristics.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Overall sample size was 426 with 59.9% taking aripiprazole (n\u2009=\u2009255) and 40.1% (n\u2009=\u2009171) taking another atypical antipsychotic (olanzapine (n\u2009=\u200919), quetiapine (n\u2009=\u2009127), risperidone (n\u2009=\u200914) or ziprasidone (n\u2009=\u200911)). Of the SF-12 domains, mean mental component summary (MCS) score (p\u2009=\u2009.018), bodily pain (p\u2009=\u2009.047), general health (p\u2009=\u2009.009) and emotional role limitations (p\u2009=\u2009.009) were found to be significantly higher in aripiprazole users indicating better HRQoL compared to other atypical antipsychotics. After controlling for demographic and health characteristics, patients taking aripiprazole reported significantly higher mean mental SF-12 component summary (34.10 vs. 31.43, p\u2009=\u2009.018), bodily pain (55.19 vs. 49.05, p\u2009=\u2009.047), general health (50.05 vs. 43.07, p\u2009=\u2009.009), emotional role limitations (49.44 vs. 41.83, p\u2009=\u2009.009), and SF-6D utility scores (0.59 vs. 0.56, p\u2009=\u2009.042).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Comparison of patients taking aripiprazole with a cohort of patients using another AA for depression demonstrated that aripiprazole was independently associated with better (both statistically and clinically) HRQoL and health utilities.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/1477-7525-10-81","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T15:53:40Z","timestamp":1342540420000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of health-related quality of life among patients using atypical antipsychotics for treatment of depression: results from the National Health and Wellness Survey"],"prefix":"10.1186","volume":"10","author":[{"given":"Iftekhar","family":"Kalsekar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Samuel","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"DiBonaventura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay","family":"Bates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Forbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tony","family":"Hebden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,7,17]]},"reference":[{"key":"939_CR1","doi-asserted-by":"publisher","first-page":"3095","DOI":"10.1001\/jama.289.23.3095","volume":"289","author":"RC Kessler","year":"2003","unstructured":"Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, Rush AJ, Walters EE, Wang PS: National Comporbidity Survey Replication: The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289: 3095\u20133105. 10.1001\/jama.289.23.3095","journal-title":"JAMA"},{"key":"939_CR2","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/archpsyc.58.9.844","volume":"58","author":"U Osby","year":"2001","unstructured":"Osby U, Brandt L, Corriea N, Ekbom A, Sparen P: Excess mortality in bipolar and unipolar disorder in Sweden. Arch Gen Psychiatry 2001, 58: 844\u2013850. 10.1001\/archpsyc.58.9.844","journal-title":"Arch Gen Psychiatry"},{"key":"939_CR3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2165\/00019053-200725010-00003","volume":"25","author":"JM Donohue","year":"2007","unstructured":"Donohue JM, Pincus HA: Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics 2007, 25: 7\u201324. 10.2165\/00019053-200725010-00003","journal-title":"Pharmacoeconomics"},{"key":"939_CR4","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/00005650-200007000-00008","volume":"38","author":"LA Lenert","year":"2000","unstructured":"Lenert LA, Sherbourne CD, Sugar C, Wells KB: Estimation of utilities for the effects of depression from the SF-12. Med Care 2000, 38: 763\u2013770. 10.1097\/00005650-200007000-00008","journal-title":"Med Care"},{"issue":"11","key":"939_CR5","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1176\/appi.ajp.163.11.1905","volume":"163","author":"AJ Rush","year":"2006","unstructured":"Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME, Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006, 163(11):1905\u20131917. 10.1176\/appi.ajp.163.11.1905","journal-title":"Am J Psychiatry"},{"key":"939_CR6","first-page":"CD008121","volume":"12","author":"K Komossa","year":"2010","unstructured":"Komossa K, Depping AM, Gaudchau A, Kissling W, Leucht S: Second-generation antipsychotics for major depressive disorder and dysthymia. Cochrane Database Syst Rev 2010, 12: CD008121.","journal-title":"Cochrane Database Syst Rev"},{"key":"939_CR7","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/YCO.0b013e3283413505","volume":"24","author":"J Chen","year":"2011","unstructured":"Chen J, Gao K, Kemp DE: Second-generation antipsychotics in major depressive disorder: update and clinical perspective. Curr Opin Psychiatry 2011, 24: 10\u201317. 10.1097\/YCO.0b013e3283413505","journal-title":"Curr Opin Psychiatry"},{"key":"939_CR8","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1176\/appi.ajp.2009.09030312","volume":"166","author":"JC Nelson","year":"2009","unstructured":"Nelson JC, Papakostas GI: Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am J Psychiatry 2009, 166: 980\u2013991. 10.1176\/appi.ajp.2009.09030312","journal-title":"Am J Psychiatry"},{"key":"939_CR9","volume-title":"Eur Arch Psychiatry Clin Neurosci","author":"TC Baghai","year":"2011","unstructured":"Baghai TC, Biler P, Baldwin DS, Bauer M, Goodwin GM, Fountoulakis KN, Kasper S, Leonard BE, Malt UF, Stein DJ, Versiani M, Moller HJ: Executive summary of the report by the WPA section on pharmacopyschiatry on general and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders. Eur Arch Psychiatry Clin Neurosci 2011. epub"},{"key":"939_CR10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.2165\/11538980-000000000-00000","volume":"25","author":"CU Pae","year":"2011","unstructured":"Pae CU, Forbes A, Patkar AA: Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 2011, 25: 109\u2013127. 10.2165\/11538980-000000000-00000","journal-title":"CNS Drugs"},{"key":"939_CR11","doi-asserted-by":"publisher","first-page":"709","DOI":"10.3111\/13696998.2010.535576","volume":"13","author":"MD DiBonaventura","year":"2010","unstructured":"DiBonaventura MD, Wagner JS, Yuan Y, L\u2019 italien G, Langley P, Ray Kim W: Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 2010, 13: 709\u2013718. 10.3111\/13696998.2010.535576","journal-title":"J Med Econ"},{"key":"939_CR12","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1097\/JOM.0b013e318229aae4","volume":"53","author":"EA Finkelstein","year":"2011","unstructured":"Finkelstein EA, Allaire BT, DiBonaventura MD, Burgess SM: Direct and indirect costs and potential cost savings of laparoscopic adjustable gastric banding among obese patients with diabetes. J Occup Environ Med 2011, 53: 1025\u20131029. 10.1097\/JOM.0b013e318229aae4","journal-title":"J Occup Environ Med"},{"key":"939_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s11136-009-9462-6","volume":"18","author":"SC Bolge","year":"2009","unstructured":"Bolge SC, Doan JF, Kannan H, Baran RW: Association of insomnia with quality of life, work productivity, and activity impairment. Qual Life Res 2009, 18: 415\u2013422. 10.1007\/s11136-009-9462-6","journal-title":"Qual Life Res"},{"key":"939_CR14","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware","year":"1996","unstructured":"Ware J, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34: 220\u2013233. 10.1097\/00005650-199603000-00003","journal-title":"Med Care"},{"key":"939_CR15","first-page":"911","volume":"33","author":"CA Sugar","year":"1998","unstructured":"Sugar CA, Sturm R, Lee TT, Sherbourne CD, Olshen RA, Wells KB, Lenert LA: Empirically defined health states for depression from the SF-12. Health Serv Res 1998, 33: 911\u2013928.","journal-title":"Health Serv Res"},{"key":"939_CR16","first-page":"S23","volume":"26","author":"SH Kennedy","year":"2001","unstructured":"Kennedy SH, Eisfel BS, Cooke RG: Quality of life: an important dimension in assessing the treatment of depression? J Psychiatry Neurosci 2001, 26: S23-S28.","journal-title":"J Psychiatry Neurosci"},{"key":"939_CR17","volume-title":"How to Score Version 2 of the SF-12\u00ae Health Survey (With a Supplement Documenting Version 1). QualityMetric","author":"JE Ware","year":"2002","unstructured":"Ware JE, Kosinski M, Turner-Bowker DM, Gandek B: How to Score Version 2 of the SF-12\u00ae Health Survey (With a Supplement Documenting Version 1). QualityMetric. Lincoln, R.I; 2002."},{"key":"939_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","volume":"42","author":"J Brazier","year":"2004","unstructured":"Brazier J, Roberts J, Deverill M: The estimation of a preference-based measure of health from the SF-12. Med Care 2004, 42: 851\u2013859. 10.1097\/01.mlr.0000135827.18610.0d","journal-title":"Med Care"},{"key":"939_CR19","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1477-7525-1-4","volume":"1","author":"SJ Walters","year":"2003","unstructured":"Walters SJ, Brazier JE: What is the relationship between the minimally important difference and health state utlity values? The case of the SF-6D. Health Qual Life Outcomes 2003, 1: 4. 10.1186\/1477-7525-1-4","journal-title":"Health Qual Life Outcomes"},{"key":"939_CR20","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"ME Charlson","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, Mackenzie CR: A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40: 373\u2013383. 10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"939_CR21","first-page":"440","volume":"10","author":"M Thase","year":"2008","unstructured":"Thase M, Trivedi M, Nelson C, Fava M, Swanink R, Tran QV, Pikalov A, Yang H, Carlson BX, Marcus RN, Berman RM: Examining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies. Prim Care Comp JCP 2008, 10: 440\u2013447.","journal-title":"Prim Care Comp JCP"},{"key":"939_CR22","volume-title":"Clin Ther","author":"Y Jing","year":"2011","unstructured":"Jing Y, Kalsekar I, Curkendall SM, Carls GS, Bagalman E, Forbes RA: Intent-to-treat analysis of health care expenditures of patients treated with atypical antipsychotics as adjunctive therapy in depression. Clin Ther 2011. epub"},{"key":"939_CR23","doi-asserted-by":"publisher","first-page":"A113","DOI":"10.1016\/S1098-3015(10)72544-4","volume":"13","author":"C Taneja","year":"2010","unstructured":"Taneja C, Oster G, Jing Y, Baker RA, Forbes RA, Papakostas GI: Cost-effectiveness of atypical antipsychotics as adjunctive therapy in adult patients with major depressive disorder (MDD) [abstract]. Value in Health 2010, 13: A113-A113.","journal-title":"Value in Health"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/1477-7525-10-81.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T19:28:04Z","timestamp":1630524484000},"score":1,"resource":{"primary":{"URL":"https:\/\/hqlo.biomedcentral.com\/articles\/10.1186\/1477-7525-10-81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7,17]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["939"],"URL":"https:\/\/doi.org\/10.1186\/1477-7525-10-81","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,7,17]]},"assertion":[{"value":"4 January 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2012","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2012","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"81"}}